Tag Archives: Pfizer

Patients as Partners® Europe Announces the Launch of 8th Annual Meeting with 2024 Keynotes and Topics

(IN BRIEF) The Conference Forum announced the launch of the 8th annual Patients as Partners® Europe meeting, scheduled for May 14-15, 2024, at Plaisterers’ Hall in London, England. This event brings together pharma R&D and patient advocacy to discuss patient … Read the full press release

ViiV Healthcare Receives Chinese Approval for Long-Acting HIV Treatment Vocabria and Rekambys

(IN BRIEF) ViiV Healthcare has received approval from China’s National Medical Products Administration (NMPA) for Vocabria (cabotegravir) in combination with Rekambys (rilpivirine), marking the first complete long-acting HIV-1 injectable treatment in China. This approval allows people living with HIV in … Read the full press release

Pfizer and BioNTech Report Promising Results for mRNA-Based Combination Vaccine Against Influenza and COVID-19

(IN BRIEF) Pfizer and BioNTech have announced positive topline results from a Phase 1/2 study of their mRNA-based combination vaccine program for influenza and COVID-19. The lead formulations showed robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. … Read the full press release

GSK’s ViiV Healthcare to Share Latest Advances in HIV Treatment and Prevention at EACS 2023

(IN BRIEF) ViiV Healthcare, a global specialist HIV company, will present 23 abstracts at the 19th Annual European AIDS Conference (EACS 2023). These abstracts will cover various aspects of HIV treatment and prevention, including real-world data on long-acting and 2-drug … Read the full press release

Alexion and AstraZeneca Acquire Rare Disease Gene Therapy Portfolio from Pfizer for $1 Billion

(IN BRIEF) Alexion, in collaboration with AstraZeneca Rare Disease, has finalized an agreement to acquire a collection of preclinical rare disease gene therapy programs and related technologies from Pfizer Inc. This strategic move combines the expertise of Alexion and AstraZeneca … Read the full press release

EU Clears BioNTech-Pfizer’s Adapted Comirnaty XBB.1.5 COVID-19 Vaccine for Fall Campaigns

(IN BRIEF) The European Union Commission has given the green light for the use of the adapted Comirnaty XBB.1.5 COVID-19 vaccine, developed by BioNTech-Pfizer, in Member States’ upcoming fall vaccination campaigns. This marks the third adaptation of the Comirnaty vaccine … Read the full press release

EMA Recommends Pfizer and BioNTech’s Omicron XBB.1.5-Adapted COVID-19 Vaccine for Approval

(IN BRIEF) Pfizer and BioNTech have received a recommendation for marketing authorization from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for their Omicron XBB.1.5-adapted monovalent COVID-19 vaccine. The recommendation includes the administration of a single … Read the full press release

BioNTech Q2 2023 update: Advances Oncology Pipeline and Prepares for Omicron-Adapted COVID-19 Vaccine Launch

(IN BRIEF) BioNTech reported its second-quarter 2023 financial results and corporate update, highlighting significant pipeline advancements in oncology with the initiation of BNT316/ONC-392 Phase 3 pivotal trial and positive data updates across multiple technology platforms. The company also prepares for … Read the full press release

Tony Wood tritt die Nachfolge von Dr. Hal Barron als Chief Scientific Officer bei GlaxoSmithKline R&D an

Tony Wood übernimmt im August 2022 die volle Verantwortung für die F&E von GSK Hal Barron wechselt im August 2022 vom CSO zu einem GSK Non-Executive Director mit zusätzlichen Verantwortlichkeiten zur Unterstützung von Forschung und Entwicklung (PRESSEMITTEILUNG) LONDON, 19-Jan-2022 — … Read the full press release

Tony Wood to succeed Dr Hal Barron as Chief Scientific Officer at GlaxoSmithKline R&D

Tony Wood to assume full accountability for GSK R&D in August 2022 Hal Barron to transition in August 2022 from CSO to a GSK Non-Executive Director with additional responsibilities to support R&D (PRESS RELEASE) LONDON, 19-Jan-2022 — /EuropaWire/ — GlaxoSmithKline … Read the full press release

Patients and R&D Leaders Jointly Present at EU Conference on Progress with Patient-Input to Transform Medicine Development

(PRESS RELEASE) New York, NY, United States, 5-Jan-2022 — /EuropaWire/ — The Conference Forum announced the launch of the 6th annual EU Patients as Partners in Medicines Development conference to take place virtually on January 24-25th, 2022 GMT time. ​​This … Read the full press release

Novartis and Pfizer announce clinical development agreement for the treatment of NASH

Agreement includes a clinical trial to evaluate a combination of tropifexor (LJN452) and one or more Pfizer compounds for the treatment of non-alcoholic steatohepatitis (NASH) Novartis has a leading development portfolio in non-viral liver diseases, including NASH There are currently no … Read the full press release

Ovarian Cancer: Merck, Pfizer initiate Phase III study JAVELIN Ovarian 100

First Phase III trial evaluating the addition of an immune checkpoint inhibitor to standard of care in first-line ovarian cancer New investigational regimen will evaluate avelumab in extending progression-free survival in treatment-naïve women Darmstadt, Germany and New York, US, 07-Jul-2016 … Read the full press release

GSK and Pfizer owned ViiV Healthcare announced US regulatory submission for STR combining dolutegravir with abacavir and lamivudine for people living with HIV

London, UK, 23-10-2013 — /EuropaWire/ — ViiV Healthcare today announced the submission of a regulatory application in the United States for its investigational single-tablet regimen (STR) combining dolutegravir, abacavir and lamivudine for the treatment of people living with HIV-1. This New Drug … Read the full press release